Developer docs
API playgroundTry for free, no card

Search company profiles

ANANDA Scientific

Full company profile

uuid0003bw3

Namestring
ANANDA Scientific
Legal namestring
ANANDA Scientific Inc.
Company typeenum
Private
Founded yearint
2008
Short descriptiontext

ANANDA Scientific is a Colorado-based biopharmaceutical company developing CBD-based investigational drugs (Nantheia™ ATL5 and A1002N5S) using its patented Liquid Structure™ delivery platform, with six FDA-approved clinical trials in PTSD, opioid use disorder, social anxiety disorder, radiculopathic pain, and smoking cessation across NYU, UCLA, Mt. Sinai, UNMC, and Yale, plus a parallel nutraceutical OTC business distributed via Maypro Industries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEnglewood, United States
HQ citystring
Englewood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid pharmaceutical research, drug delivery technology, CBD clinical trials, neuropsychiatric therapeutics, nutraceutical CBD products
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Cannabinoid Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical / Investigational Drug Development
TypeLicensing Royalties
Description

Revenue from pharmaceutical products is pre-commercial as ANANDA Scientific is currently in the clinical trial stage. The company is developing Nantheia™ investigational drugs (Nantheia™ A1002N5S and Nantheia™ ATL5) through FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. Anticipated future revenue will come from FDA-approved pharmaceutical drug sales upon successful completion of clinical trials and regulatory approval.

anandascientific.com
2Nutraceutical Over-the-Counter (OTC) Products
TypeOne Time License
Description

Growing pipeline of nutraceutical OTC products leveraging Liquid Structure™ technology for enhanced bioavailability. Products successfully launched in the US, Australia, and UK markets, with expansion planned into EU, China, Africa, and other Asian markets. Revenue generated from direct consumer sales and through distribution partners.

anandascientific.com
3Nutraceutical Ingredient Sales via Distribution Partner
TypeTransaction Fee
Description

Bulk ingredient sales of Liquid Structure™ CBD formulations through Maypro Industries, ANANDA's U.S. sales and distribution partner. Maypro is one of the largest global suppliers of nutraceutical ingredients, with six strategically located companies in the US, Japan and China.

anandascientific.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Nantheia™ ATL5
Description

Pharmaceutical Grade Cannabidiol Isolate combined with Liquid Structure™ Technology; 100mg CBD per softgel; under evaluation in clinical trials for PTSD, Social Anxiety Disorder, and Opioid Use Disorder.

anandascientific.com
+1 more record
Core offering1 text field

ANANDA Scientific develops and commercializes cannabinoid-based pharmaceutical and nutraceutical products built on its proprietary Liquid Structure™ delivery technology. The pharmaceutical business operates investigational CBD drugs (Nantheia™ ATL5 and Nantheia™ A1002N5S) through FDA-approved clinical trials at leading academic medical centers for neuropsychiatric indications including PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The nutraceutical line sells bio-enhanced, taste-masked and beverage-stable CBD over-the-counter products through its own e-commerce, US distribution partner Maypro Industries, retail in Australia and the UK, and future Europe/MENA partner Benta SAS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Pre-clinical and initial clinical studies demonstrate that Liquid Structure™ delivery technology enhances the effectiveness and stability of CBD
+5 more records
Product overview1 text field

ANANDA Scientific is a research-driven biopharmaceutical company developing life-changing medicines for unmet medical needs in neuropsychiatric disorders. The company's product portfolio centers on its patented Liquid Structure™ Technology platform, a drug delivery system that enhances bioavailability, consistent absorption, and shelf-life stability of cannabinoids. The two flagship investigational drug products are Nantheia™ ATL5 (100mg CBD per softgel) and Nantheia™ A1002N5S (50mg CBD per softgel), both leveraging the Liquid Structure™ technology and currently undergoing multiple FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The company also maintains a growing pipeline of nutraceutical over-the-counter products.

Product and service4 records
1Nantheia™ ATL5
CategoryInvestigational Pharmaceutical Drug
Description

Pharmaceutical-grade investigational drug combining 100mg Pharmaceutical Grade Cannabidiol Isolate per softgel with ANANDA's patented Liquid Structure™ delivery technology in soft gelatin capsules. Currently under evaluation in multiple FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation at NYU, UCLA, Mt. Sinai, UNMC, and Yale.

2Nantheia™ A1002N5S
CategoryInvestigational Pharmaceutical Drug
Description

Pharmaceutical-grade investigational drug combining 50mg Cannabidiol Isolate per softgel with ANANDA's patented Liquid Structure™ delivery technology in soft gelatin capsules. Currently under evaluation in multiple FDA-approved clinical trials at NYU Grossman School of Medicine for PTSD, Social Anxiety Disorder, and Radiculopathic Pain as an opioid-sparing treatment.

3Taste-Masked CBD Formulation
CategoryNutraceutical CBD Over-the-Counter Product
Description

Water-stable, high-bioavailability Liquid Structure™ CBD nutraceutical product with proprietary molecular-level taste-masking that places CBD constructs inside unique molecular envelopes to hide the characteristic bitter taste from taste buds, while maintaining water solubility suitable for beverages, tinctures, and sublingual preparations.

4Beverage-Stable CBD Formulation
CategoryNutraceutical CBD Over-the-Counter Product
Description

Water-stable Liquid Structure™ CBD nutraceutical formulation that stays in solution for years in plastic, glass, and aluminum packaging without adhering to container walls, designed for beverage, tincture, and sublingual applications and protected by US Patents 7,182,950 and 10,149,824.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Benta SAS (France)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-14
Description

MOU signed with Benta SAS, a France-based pharmaceutical company, to explore collaboration for accelerating development and future availability of Nantheia™ for PTSD treatment in Europe and the MENA region. ANANDA will lead all aspects of clinical development while Benta will focus on manufacturing expertise and infrastructure for potential future product scale-up and regional distribution.

anandascientific.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-17
Description

Clinical trial evaluating Nantheia™ ATL5 co-administered with THC for treating co-occurring Opioid Use Disorder and Chronic Pain (NCT06544291), led by Joao P. De Aquino MD, Director of the Pain and Addiction Interaction Neurosciences (PAIN) Laboratory. Randomized, double-blind, placebo-controlled, cross-over study with participants maintained on stable methadone doses. Funded by NIDA.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-17
Description

Phase II clinical trial evaluating Nantheia™ ATL5 for PTSD with 240 participants planned (NCT05269459), led by Mathew Rizzo MD. FDA IND approved. The trial has a diverse team spanning neuroscience, psychiatry, neuroimaging, and public policy. This is ANANDA's second PTSD trial, allowing comparison with NYU's Nantheia™ A1002N5S trial.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-19
Description

Phase I trial completed at Mt. Sinai evaluating pharmacokinetic profile, safety, and drug tolerability of Nantheia™ ATL5 versus Epidiolex™ in 24 subjects for Opioid Use Disorder (NCT05023070), led by Yasmin L Hurd PhD, Ward-Coleman Chair of Translational Neuroscience and Director of the Addiction Institute at Mount Sinai. Funded by NIDA.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-29
Description

Clinical trial collaboration with the Jane and Terry Semel Institute at UCLA for: (1) Phase I/II trial evaluating Nantheia™ ATL5 as adjunctive treatment for Opioid Use Disorder (NCT03787628), led by Edythe London PhD and Richard De La Garza II PhD; (2) Clinical trial for smoking cessation evaluating Nantheia™ ATL5 800mg CBD daily for 8 weeks (NCT06218056), led by Edythe London PhD. Funded by NIDA and Center for Medicinal Cannabis Research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Multiple clinical trial collaborations: (1) Phase II trial evaluating Nantheia™ A1002N5S for PTSD with 120 participants (NCT04550377), led by Charles Marmar MD and Esther Blessing MD PhD; (2) Phase II trial for Social Anxiety Disorder with 60 participants (NCT05571592), led by Naomi Simon MD MSc and Esther Blessing MD PhD; (3) Trial evaluating Nantheia™ A1002N5S for opioid-sparing in radiculopathic pain (NCT04760613), led by Stephen Ross MD. Funded in part by NCCIH/NIH.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-11-08
Description

Appointment of Maypro Industries as ANANDA's U.S. sales and distribution partner for bulk nutraceutical ingredient products. Maypro is one of the largest global suppliers of nutraceutical ingredients, with six strategically located companies in the US, Japan and China, and a highly selective portfolio of patented and branded ingredients backed by clinical data.

Strategic tierCoreTypeTechnology or Integration
Description

Licensing agreement for Liquid Structure™ delivery technology from Lyotropic Delivery Systems (LDS) Ltd. and The Hebrew University of Jerusalem. LDS founder Professor Nissim Garti is the inventor of the technology. ANANDA uses this patented technology across its entire pharmaceutical and nutraceutical product portfolio. Pre-clinical and initial clinical studies show the technology enhances the effectiveness and stability of CBD.

9Hadassah Medical Hospital (Jerusalem, Israel)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration with Hadassah Medical Hospital for Phase I human clinical trial assessing bioavailability and safety of ANANDA's Liquid Structure™ CBD formulation versus CBD in olive oil. Completed in 2020. Additional preclinical studies exploring modes of action for Liquid Structure™ formulations were completed in 2022. Hadassah Clinical Research Center is a leading early-phase clinical facility in Israel.

anandascientific.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Preclinical studies with proprietary Liquid Structure™ cannabinoid formulations to further understand the mode of action of the proprietary formulations in the body, led by Mark Kindy PhD.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired GW Pharmaceuticals in 2021 for ~$7.2B, making it the owner of Epidiolex®, the first FDA-approved CBD therapeutic and a direct comparator to ANANDA's Nantheia™ programs in CNS indications. Most direct commercial benchmark for ANANDA's pharmaceutical ambitions.

TypeDirect peer
Description

Clinical-stage cannabinoid therapeutics company developing transdermal CBD for Fragile X syndrome and other neuropsychiatric conditions. Closest direct peer in cannabinoid CNS drug development, though focused on different delivery (transdermal vs. oral softgel) and indications.

TypeBroad incumbent
Description

Specialty CNS biopharmaceutical company focused on neuropsychiatric disorders including depression and epilepsy. Comparable business model targeting CNS indications with novel mechanisms, providing a relevant benchmark for ANANDA's specialty pharma positioning.

TypeDirect peer
Description

Specialty pharmaceutical company developing CNS therapeutics including ganaxolone for seizure disorders. Comparable clinical-stage CNS biopharma with FDA-approved product (Ztalmy®), relevant as a benchmark for ANANDA's regulatory and commercial pathway in CNS.

TypeDirect peer
Description

Leading CBD wellness and nutraceutical brand with established US retail distribution. Most direct comparable in ANANDA's nutraceutical OTC business, with similar target consumer segments and product positioning in premium CBD wellness.

TypeDirect peer
Description

Specialty CBD consumer products company with PlusCBD™ brand and pharmaceutical R&D division developing CBD-based therapeutics. Combines consumer nutraceutical business with pharmaceutical development, closely mirroring ANANDA's dual business model.

TypeBroad incumbent
Description

Large-scale cannabis company with pharmaceutical R&D division. Comparable in pursuing cannabinoid-based pharmaceutical development, though broader cannabis industry exposure makes it a broader market incumbent rather than a focused CBD therapeutics peer.

8PurePlay Capital / Tetra Bio-Pharma
TypeEmerging player
Description

Canadian cannabinoid-derived pharmaceutical company developing prescription cannabinoid drugs. Comparable emerging player in cannabinoid drug development with regulatory pathway focus, relevant peer for ANANDA's pharmaceutical business unit.

TypeOthers
Description

Israel-based licensor of the Liquid Structure™ technology to ANANDA. As the technology partner, LDS is an ecosystem participant rather than a competitor, but provides relevant context on the platform's underlying scientific foundation.

TypeOthers
Description

US distribution partner for ANANDA's bulk nutraceutical ingredients. As a major nutraceutical ingredient distributor serving similar wellness brands, Maypro is a channel partner and ecosystem participant relevant to ANANDA's go-to-market infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ANANDA Scientific

Cannabinoid Pharmaceuticalsanandascientific.com

ANANDA Scientific is a Colorado-based biopharmaceutical company developing CBD-based investigational drugs (Nantheia™ ATL5 and A1002N5S) using its patented Liquid Structure™ delivery platform, with six FDA-approved clinical trials in PTSD, opioid use disorder, social anxiety disorder, radiculopathic pain, and smoking cessation across NYU, UCLA, Mt. Sinai, UNMC, and Yale, plus a parallel nutraceutical OTC business distributed via Maypro Industries.

ANANDA Scientific firmographics

Firmographics
Name
ANANDA Scientific
Legal name
ANANDA Scientific Inc.
Website
https://anandascientific.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
ANANDA Scientific is a Colorado-based biopharmaceutical company developing CBD-based investigational drugs (Nantheia™ ATL5 and A1002N5S) using its patented Liquid Structure™ delivery platform, with six FDA-approved clinical trials in PTSD, opioid use disorder, social anxiety disorder, radiculopathic pain, and smoking cessation across NYU, UCLA, Mt. Sinai, UNMC, and Yale, plus a parallel nutraceutical OTC business distributed via Maypro Industries.
Ownership category
akta.pro rank

ANANDA Scientific industry classification

Industry
Product category
Cannabinoid Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)

Keywords

  • Cannabinoid pharmaceutical research
  • Drug delivery technology
  • CBD clinical trials
  • Neuropsychiatric therapeutics
  • Nutraceutical CBD products

Where ANANDA Scientific is headquartered

Location

Headquarters

HQ city
Englewood
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ANANDA Scientific business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical / Investigational Drug Development: Revenue from pharmaceutical products is pre-commercial as ANANDA Scientific is currently in the clinical trial stage. The company is developing Nantheia™ investigational drugs (Nantheia™ A1002N5S and Nantheia™ ATL5) through FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. Anticipated future revenue will come from FDA-approved pharmaceutical drug sales upon successful completion of clinical trials and regulatory approval.
  2. Nutraceutical Over-the-Counter (OTC) Products: Growing pipeline of nutraceutical OTC products leveraging Liquid Structure™ technology for enhanced bioavailability. Products successfully launched in the US, Australia, and UK markets, with expansion planned into EU, China, Africa, and other Asian markets. Revenue generated from direct consumer sales and through distribution partners.
  3. Nutraceutical Ingredient Sales via Distribution Partner: Bulk ingredient sales of Liquid Structure™ CBD formulations through Maypro Industries, ANANDA's U.S. sales and distribution partner. Maypro is one of the largest global suppliers of nutraceutical ingredients, with six strategically located companies in the US, Japan and China.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

ANANDA Scientific product offering

Product offering

Core offering

ANANDA Scientific develops and commercializes cannabinoid-based pharmaceutical and nutraceutical products built on its proprietary Liquid Structure™ delivery technology. The pharmaceutical business operates investigational CBD drugs (Nantheia™ ATL5 and Nantheia™ A1002N5S) through FDA-approved clinical trials at leading academic medical centers for neuropsychiatric indications including PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The nutraceutical line sells bio-enhanced, taste-masked and beverage-stable CBD over-the-counter products through its own e-commerce, US distribution partner Maypro Industries, retail in Australia and the UK, and future Europe/MENA partner Benta SAS.

Product overview

ANANDA Scientific is a research-driven biopharmaceutical company developing life-changing medicines for unmet medical needs in neuropsychiatric disorders. The company's product portfolio centers on its patented Liquid Structure™ Technology platform, a drug delivery system that enhances bioavailability, consistent absorption, and shelf-life stability of cannabinoids. The two flagship investigational drug products are Nantheia™ ATL5 (100mg CBD per softgel) and Nantheia™ A1002N5S (50mg CBD per softgel), both leveraging the Liquid Structure™ technology and currently undergoing multiple FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The company also maintains a growing pipeline of nutraceutical over-the-counter products.

Differentiator

Problem solved

Functional benefit

Brands

  • Nantheia™ ATL5: Pharmaceutical Grade Cannabidiol Isolate combined with Liquid Structure™ Technology; 100mg CBD per softgel; under evaluation in clinical trials for PTSD, Social Anxiety Disorder, and Opioid Use Disorder.
  • Nantheia™ A1002N5S

Products and services

  • Nantheia™ ATL5 Pharmaceutical-grade investigational drug combining 100mg Pharmaceutical Grade Cannabidiol Isolate per softgel with ANANDA's patented Liquid Structure™ delivery technology in soft gelatin capsules. Currently under evaluation in multiple FDA-approved clinical trials for PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation at NYU, UCLA, Mt. Sinai, UNMC, and Yale.
  • Nantheia™ A1002N5S Pharmaceutical-grade investigational drug combining 50mg Cannabidiol Isolate per softgel with ANANDA's patented Liquid Structure™ delivery technology in soft gelatin capsules. Currently under evaluation in multiple FDA-approved clinical trials at NYU Grossman School of Medicine for PTSD, Social Anxiety Disorder, and Radiculopathic Pain as an opioid-sparing treatment.
  • Taste-Masked CBD Formulation Water-stable, high-bioavailability Liquid Structure™ CBD nutraceutical product with proprietary molecular-level taste-masking that places CBD constructs inside unique molecular envelopes to hide the characteristic bitter taste from taste buds, while maintaining water solubility suitable for beverages, tinctures, and sublingual preparations.
  • Beverage-Stable CBD Formulation Water-stable Liquid Structure™ CBD nutraceutical formulation that stays in solution for years in plastic, glass, and aluminum packaging without adhering to container walls, designed for beverage, tincture, and sublingual applications and protected by US Patents 7,182,950 and 10,149,824.

Quantifiable outcome

  • Pre-clinical and initial clinical studies demonstrate that Liquid Structure™ delivery technology enhances the effectiveness and stability of CBD
  • +5 more outcomes

Companies that use ANANDA Scientific

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

ANANDA Scientific technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

ANANDA Scientific partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • Benta SAS (France)minorChannel Partner/ Reseller/ Distributor · 14 November 2024MOU signed with Benta SAS, a France-based pharmaceutical company, to explore collaboration for accelerating development and future availability of Nantheia™ for PTSD treatment in Europe and the MENA region. ANANDA will lead all aspects of clinical development while Benta will focus on manufacturing expertise and infrastructure for potential future product scale-up and regional distribution.
  • Yale School of MedicinecoreStrategic or Co-development Partner · 17 October 2024Clinical trial evaluating Nantheia™ ATL5 co-administered with THC for treating co-occurring Opioid Use Disorder and Chronic Pain (NCT06544291), led by Joao P. De Aquino MD, Director of the Pain and Addiction Interaction Neurosciences (PAIN) Laboratory. Randomized, double-blind, placebo-controlled, cross-over study with participants maintained on stable methadone doses. Funded by NIDA.
  • University of Nebraska Medical Center (UNMC)coreStrategic or Co-development Partner · 17 May 2022Phase II clinical trial evaluating Nantheia™ ATL5 for PTSD with 240 participants planned (NCT05269459), led by Mathew Rizzo MD. FDA IND approved. The trial has a diverse team spanning neuroscience, psychiatry, neuroimaging, and public policy. This is ANANDA's second PTSD trial, allowing comparison with NYU's Nantheia™ A1002N5S trial.
  • Icahn School of Medicine at Mt. SinaicoreStrategic or Co-development Partner · 19 October 2021Phase I trial completed at Mt. Sinai evaluating pharmacokinetic profile, safety, and drug tolerability of Nantheia™ ATL5 versus Epidiolex™ in 24 subjects for Opioid Use Disorder (NCT05023070), led by Yasmin L Hurd PhD, Ward-Coleman Chair of Translational Neuroscience and Director of the Addiction Institute at Mount Sinai. Funded by NIDA.
  • Geffen School of Medicine at UCLAcoreStrategic or Co-development Partner · 29 September 2021Clinical trial collaboration with the Jane and Terry Semel Institute at UCLA for: (1) Phase I/II trial evaluating Nantheia™ ATL5 as adjunctive treatment for Opioid Use Disorder (NCT03787628), led by Edythe London PhD and Richard De La Garza II PhD; (2) Clinical trial for smoking cessation evaluating Nantheia™ ATL5 800mg CBD daily for 8 weeks (NCT06218056), led by Edythe London PhD. Funded by NIDA and Center for Medicinal Cannabis Research.
  • NYU Grossman School of MedicinecoreStrategic or Co-development Partner · 12 January 2021Multiple clinical trial collaborations: (1) Phase II trial evaluating Nantheia™ A1002N5S for PTSD with 120 participants (NCT04550377), led by Charles Marmar MD and Esther Blessing MD PhD; (2) Phase II trial for Social Anxiety Disorder with 60 participants (NCT05571592), led by Naomi Simon MD MSc and Esther Blessing MD PhD; (3) Trial evaluating Nantheia™ A1002N5S for opioid-sparing in radiculopathic pain (NCT04760613), led by Stephen Ross MD. Funded in part by NCCIH/NIH.
  • Maypro IndustriescoreChannel Partner/ Reseller/ Distributor · 8 November 2019Appointment of Maypro Industries as ANANDA's U.S. sales and distribution partner for bulk nutraceutical ingredient products. Maypro is one of the largest global suppliers of nutraceutical ingredients, with six strategically located companies in the US, Japan and China, and a highly selective portfolio of patented and branded ingredients backed by clinical data.
  • Lyotropic Delivery Systems (LDS) Ltd. (Jerusalem, Israel)coreTechnology or IntegrationLicensing agreement for Liquid Structure™ delivery technology from Lyotropic Delivery Systems (LDS) Ltd. and The Hebrew University of Jerusalem. LDS founder Professor Nissim Garti is the inventor of the technology. ANANDA uses this patented technology across its entire pharmaceutical and nutraceutical product portfolio. Pre-clinical and initial clinical studies show the technology enhances the effectiveness and stability of CBD.
  • Hadassah Medical Hospital (Jerusalem, Israel)coreStrategic or Co-development PartnerClinical collaboration with Hadassah Medical Hospital for Phase I human clinical trial assessing bioavailability and safety of ANANDA's Liquid Structure™ CBD formulation versus CBD in olive oil. Completed in 2020. Additional preclinical studies exploring modes of action for Liquid Structure™ formulations were completed in 2022. Hadassah Clinical Research Center is a leading early-phase clinical facility in Israel.
  • University of FloridaminorStrategic or Co-development PartnerPreclinical studies with proprietary Liquid Structure™ cannabinoid formulations to further understand the mode of action of the proprietary formulations in the body, led by Mark Kindy PhD.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

ANANDA Scientific competitors and assessment

Company assessment

Broad incumbents

  • Jazz Pharmaceuticals: Acquired GW Pharmaceuticals in 2021 for ~$7.2B, making it the owner of Epidiolex®, the first FDA-approved CBD therapeutic and a direct comparator to ANANDA's Nantheia™ programs in CNS indications. Most direct commercial benchmark for ANANDA's pharmaceutical ambitions.
  • Sage Therapeutics: Specialty CNS biopharmaceutical company focused on neuropsychiatric disorders including depression and epilepsy. Comparable business model targeting CNS indications with novel mechanisms, providing a relevant benchmark for ANANDA's specialty pharma positioning.
  • Canopy Growth Corporation: Large-scale cannabis company with pharmaceutical R&D division. Comparable in pursuing cannabinoid-based pharmaceutical development, though broader cannabis industry exposure makes it a broader market incumbent rather than a focused CBD therapeutics peer.

Direct peers

  • Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics company developing transdermal CBD for Fragile X syndrome and other neuropsychiatric conditions. Closest direct peer in cannabinoid CNS drug development, though focused on different delivery (transdermal vs. oral softgel) and indications.
  • Marinus Pharmaceuticals: Specialty pharmaceutical company developing CNS therapeutics including ganaxolone for seizure disorders. Comparable clinical-stage CNS biopharma with FDA-approved product (Ztalmy®), relevant as a benchmark for ANANDA's regulatory and commercial pathway in CNS.
  • Charlotte's Web Holdings: Leading CBD wellness and nutraceutical brand with established US retail distribution. Most direct comparable in ANANDA's nutraceutical OTC business, with similar target consumer segments and product positioning in premium CBD wellness.
  • CV Sciences: Specialty CBD consumer products company with PlusCBD™ brand and pharmaceutical R&D division developing CBD-based therapeutics. Combines consumer nutraceutical business with pharmaceutical development, closely mirroring ANANDA's dual business model.

Emerging players

  • PurePlay Capital / Tetra Bio-Pharma: Canadian cannabinoid-derived pharmaceutical company developing prescription cannabinoid drugs. Comparable emerging player in cannabinoid drug development with regulatory pathway focus, relevant peer for ANANDA's pharmaceutical business unit.

Others

  • Lyotropic Delivery Systems (LDS): Israel-based licensor of the Liquid Structure™ technology to ANANDA. As the technology partner, LDS is an ecosystem participant rather than a competitor, but provides relevant context on the platform's underlying scientific foundation.
  • Maypro Industries: US distribution partner for ANANDA's bulk nutraceutical ingredients. As a major nutraceutical ingredient distributor serving similar wellness brands, Maypro is a channel partner and ecosystem participant relevant to ANANDA's go-to-market infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

ANANDA Scientific social profiles

Digital presence

ANANDA Scientific compliance and trust

Trust signal

Compliance4 records

ANANDA Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ANANDA Scientific leadership team

Management profile

Number of profiles

Profiles19 records

ANANDA Scientific funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ANANDA Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ANANDA Scientific

What does ANANDA Scientific do?

ANANDA Scientific develops and commercializes cannabinoid-based pharmaceutical and nutraceutical products built on its proprietary Liquid Structure™ delivery technology. The pharmaceutical business operates investigational CBD drugs (Nantheia™ ATL5 and Nantheia™ A1002N5S) through FDA-approved clinical trials at leading academic medical centers for neuropsychiatric indications including PTSD, Social Anxiety Disorder, Opioid Use Disorder, Radiculopathic Pain, and Smoking Cessation. The nutraceutical line sells bio-enhanced, taste-masked and beverage-stable CBD over-the-counter products through its own e-commerce, US distribution partner Maypro Industries, retail in Australia and the UK, and future Europe/MENA partner Benta SAS.

Is ANANDA Scientific a public or private company?

ANANDA Scientific is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ANANDA Scientific founded?

ANANDA Scientific was founded in 2008. It employs 1 to 10 people.

Where is ANANDA Scientific based?

ANANDA Scientific is headquartered in Englewood, United States, in the North America region.

How does ANANDA Scientific make money?

Three revenue lines are on record. Pharmaceutical / Investigational Drug Development is the primary driver. The others are nutraceutical Over-the-Counter (OTC) Products and nutraceutical Ingredient Sales via Distribution Partner.

Who are ANANDA Scientific's main competitors?

Broad incumbents on record are Jazz Pharmaceuticals, Sage Therapeutics and Canopy Growth Corporation. Direct peers are Zynerba Pharmaceuticals, Marinus Pharmaceuticals, Charlotte's Web Holdings and CV Sciences. PurePlay Capital / Tetra Bio-Pharma is listed as an emerging player. Others are Lyotropic Delivery Systems (LDS) and Maypro Industries.

Does ANANDA Scientific have an API?

No public API is recorded for ANANDA Scientific.

What industry is ANANDA Scientific in?

ANANDA Scientific's product category is Cannabinoid Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of CRANAHAC, CBD/Hemp Wellness & Supplements Retail. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic PainANANDA Scientific announced a clinical trial of Nantheia ATL5, a CBD-THC investigational drug, for co-occurring opioid use disorder and chronic pain. The randomized, double-blind, placebo-controlled study at Yale School of Medicine will test doses of CBD and THC. Funding comes from a National Institute on Drug Abuse grant.GlobeNewswireChronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the DomainDelveInsight's 2025 chronic pain pipeline report identifies 20+ companies developing 25+ drugs, including Apurano, Centrexion, and Mesoblast. Tris Pharma reported positive topline results for cebranopadol in January 2025, and ANANDA Scientific began a trial for Nantheia in October 2024.Business Wire BlogANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)ANANDA Scientific Inc. has announced the enrollment of the first patient in a clinical trial for its investigational drug Nantheia™ A1002N5S, aimed at treating Social Anxiety Disorder (SAD). The trial is funded by the National Center for Complementary and Integrative Health and will assess the drug's efficacy over a 21-day treatment period.PR NewswireANANDA Scientific Announces First Patient Enrolled in the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)ANANDA Scientific Inc. announced the enrollment of the first patient in a clinical trial evaluating Nantheia™ ATL5, an investigational CBD-based drug, as an adjunctive treatment for Opioid Use Disorder. The randomized, double-blind, placebo-controlled trial is being conducted at UCLA's Semel Institute with principal investigators Dr. Edythe London and Dr. Richard De La Garza II, funded by the National Institute on Drug Abuse. The study will evaluate CBD doses of 600 and 1200 mg/day as an adjunct to buprenorphine and naloxone therapy in patients receiving residential behavioral treatment.GlobeNewswireDennis Wong Joins ANANDA Scientific Inc. Board ofDennis Wong, CEO of Baxco Pharmaceutical, was appointed to ANANDA Scientific's Board of Directors. He will help guide the company's rapid growth, and his experience is valued for manufacturing ANANDA's investigational drugs NANETHIA A1002 and NANTHEIA ATL5, which are in six FDA-approved clinical trials.BioSpaceANANDA Scientific Appoints Sohail Zaidi as its New PresidentANANDA Scientific Inc. announced the appointment of Sohail Zaidi as its new President and Chief Financial Officer, succeeding Christopher Moore who is stepping down from the role but remaining with the company. Zaidi will oversee the company's pharmaceutical and nutraceutical business units while continuing to lead its clinical trial programs. The company plans to expand its market presence into the EU, China, Australia, and Africa.PR NewswireJohn Suh Joins ANANDA Scientific's Board of Directors as Executive DirectorANANDA Scientific Inc., a biotech pharma company headquartered in Greenwood, Colorado, announced the appointment of John Suh, former CEO of LegalZoom, to its Board of Directors as Executive Director. Suh grew LegalZoom to a market value exceeding $2 billion during his tenure as CEO from 2007 to 2019, and brings extensive experience in scaling technology companies to the biotech firm. The company stated that Suh's entrepreneurial expertise is expected to guide ANANDA in its pursuit of rapid growth and shareholder value from its clinical development program.NewswireANANDA Scientific Debuts Beverage-Stable CBD FormulationANANDA Scientific announced the launch of a new beverage-stable CBD formulation designed to maintain potency in aqueous mixtures and various packaging types. The company claims this patented technology addresses stability issues common in current market products, enabling more effective delivery of cannabinoids. This development supports ANANDA's expansion plans into international markets including China, Australia, and Africa.NewswireANANDA Scientific Launches New Taste Masked CBD FormulationANANDA Scientific launched a new taste-masked CBD formulation that incorporates its patented Liquid Structure™ technology. The water-stable CBD is commercially available and designed to hide the bitter taste, making it suitable for beverages and other oral preparations. The company plans to expand into China, Australia, and Africa.